DiscGenics
CompanyUnited States
DiscGenics develops one asset, in phase 3 (Rebonuputemcel in degenerative disc disease). Mostly cell therapy acting on stem cell maintenance; based in the United States.
- 1
- Asset
- Furthest
- Phase 3
- 3
- Trials
- 0
- Signals
Pipeline
1Allogeneic disc-derived progenitor cell therapy for disc regeneration
Phase 3, Cell therapy, Stem cell maintenance, degenerative disc disease
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms1
- Trials3
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 8 sources